Showing results (101-110 of 148) with videos related to
Sort By:
Pageof 15
Cell Death and Differentiation|June 27, 2021
TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancerTao Gui, Ming Liu, Bing Yao, et al.Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.Blood|April 24, 2009
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant functionSimone M Schoenwaelder, Yuping Yuan, Emma C Josefsson, et al.Blood|June 16, 2011
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsSimone M Schoenwaelder, Kate E Jarman, Elizabeth E Gardiner, et al.Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseAndrew W Roberts, John F Seymour, Jennifer R Brown, et al.NPJ Precision Oncology|March 16, 2023
The SMARCA4<sup>R1157W</sup> mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancerXiangwei Zeng, Bing Yao, Jianpeng Liu, et al.The Journal of Experimental Medicine|September 14, 2011
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce plateletsEmma C Josefsson, Chloé James, Katya J Henley, et al.Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.The Biochemical Journal|April 28, 2023
The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinaseCatia L Pierotti, Annette V Jacobsen, Christoph Grohmann, et al.Pageof 15